{"id":"indobufen-and-aspirin-mimetic","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal bleeding"},{"rate":null,"effect":"Dyspepsia"},{"rate":null,"effect":"Bruising/bleeding tendency"}]},"_chembl":{"chemblId":"CHEMBL1765292","moleculeType":"Small molecule","molecularWeight":"295.34"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Indobufen works by inhibiting platelet function through irreversible acetylation of cyclooxygenase enzymes, reducing thromboxane A2 synthesis and platelet aggregation. Like aspirin, it is used as an antiplatelet agent to prevent cardiovascular and cerebrovascular thrombotic events. The drug has been marketed primarily in Asia, particularly in China, for cardiovascular indications.","oneSentence":"Indobufen is a platelet aggregation inhibitor that irreversibly acetylates cyclooxygenase, similar to aspirin, to prevent thrombotic events.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:48:39.952Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of thrombotic events in cardiovascular disease"},{"name":"Secondary prevention after myocardial infarction or stroke"}]},"trialDetails":[{"nctId":"NCT03871517","phase":"PHASE4","title":"INdobufen Versus aSpirin in acUte Ischemic stRokE,INSURE","status":"COMPLETED","sponsor":"Beijing Tiantan Hospital","startDate":"2019-06-03","conditions":"Ischemic Stroke, Indobufen, Aspirin","enrollment":5438},{"nctId":"NCT04129008","phase":"PHASE4","title":"GaStroEsophageal effeCt of indobUfen Versus aspiRin in Patients Undergoing Dual antiplatElet Therapy","status":"UNKNOWN","sponsor":"Beijing Anzhen Hospital","startDate":"2019-10-17","conditions":"Coronary Artery Disease, Gastroesophageal Reflux Disease","enrollment":88}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Indobufen and aspirin mimetic","genericName":"Indobufen and aspirin mimetic","companyName":"Beijing Anzhen Hospital","companyId":"beijing-anzhen-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Indobufen is a platelet aggregation inhibitor that irreversibly acetylates cyclooxygenase, similar to aspirin, to prevent thrombotic events. Used for Prevention of thrombotic events in cardiovascular disease, Secondary prevention after myocardial infarction or stroke.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}